Cabozantinib [CABO1]
The treatment of medullary thyroid cancer where all the following criteria are met:
- This application is made by and the first cycle of systemic anti-cancer therapy with cabozantinib will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy
- This patient has a confirmed histological diagnosis of medullary thyroid carcinoma
- The patient has either metastatic disease or inoperable locally advanced disease
- The disease is progressive and is either symptomatic or imminently likely to become symptomatic
- The patient is treatment naïve to both cabozantinib and vandetanib unless the patient has had to discontinue vandetanib within 3 months of starting vandetanib because of toxicity (i.e. there is vandetanib toxicity which cannot be managed by dose delay or dose modification) and there has been no disease progression whilst on vandetanib.
- The patient has an ECOG performance status of 0 or 1 or 2.
- Cabozantinib is to be continued as long as clinical benefit is observed or until there is unacceptable toxicity or patient choice to stop treatment
- A formal medical review as to whether treatment with cabozantinib should continue or not will be scheduled to occur at least by the end of the first 8 weeks of treatment
- No treatment breaks of more than 6 weeks beyond the expected cycle length are allowed (to allow any toxicity of current therapy to settle or intercurrent comorbidities to improve)
- Cabozantinib is to be otherwise used as set out in its Summary of Product Characteristics
NHS funded From: 26 June 2018
Additional information
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.